Clinical trial · Interventional
Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy
NCT03235167CI-TRIAL-00029577unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CpG DNA | Drug | — | UNRESOLVED |
| Placebo - Concentrate | Drug | — | UNRESOLVED |
| transcatheter arterial chemoembolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CpG DNA
- description
- CpG DNA concentrate
- interventionNames
- Drug: CpG DNA
- Procedure: transcatheter arterial chemoembolization
- type
- PLACEBO_COMPARATOR
- label
- placebo
- description
- placebo concentrate
- interventionNames
- Procedure: transcatheter arterial chemoembolization
- Drug: Placebo - Concentrate
Primary outcomes (2)
- measure
- survival time
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 55 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors Exclusion Criteria: * having received previous treatment for liver cancer
References
Publications (0)
Data not yet available
No reference posted for this study.